External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the CUETO Group
NCT05864599 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 600
Last updated 2024-04-03
Summary
Independent validation of Uromonitor as a non-invasive biomarker of recurrence of Non Muscle Invasive Bladder Cancer
Conditions
- Non-muscle-invasive Bladder Cancer
Sponsors & Collaborators
-
Pharmalink
lead INDUSTRY
Principal Investigators
-
José Rubio-Briones, MD PhD · Hospital 9 d'Octubre
Eligibility
- Min Age
- 22 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-06-16
- Primary Completion
- 2024-05-31
- Completion
- 2024-06-30
Countries
- Spain
Study Locations
More Related Trials
-
Diagnostic Accuracy of Optical Coherence Tomography in Upper Urinary Tract Urothelial Carcinoma
NCT02326909 ·Status: COMPLETED ·Phase: NA
-
The Research Value of Multi-omics and Multi-modal Information in the Diagnosis and Treatment of Urinary System Tumors
NCT06490211 ·Status: RECRUITING
-
Urine-based Detection of Non-muscle Invasive Bladder
NCT03962933 ·Status: COMPLETED
-
Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
NCT05982561 ·Status: RECRUITING
-
Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder
NCT02745301 ·Status: COMPLETED
-
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
NCT05868265 ·Status: RECRUITING ·Phase: PHASE2
-
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
NCT05756569 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder Cancer
NCT03125460 ·Status: COMPLETED
-
Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
NCT06126796 ·Status: COMPLETED
-
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
NCT03219333 ·Status: COMPLETED ·Phase: PHASE2
-
Expression of MCM5 in Urine in Patients With Urothelial Cancers
NCT03796299 ·Status: UNKNOWN
-
Detecting Bladder Cancer Using the UroMark Test.
NCT02676180 ·Status: COMPLETED
-
Clinical Evaluation of the miR Sentinel BCa™ Test to Diagnose Bladder Cancer in Hematuria Patients
NCT04155359 ·Status: ACTIVE_NOT_RECRUITING
-
Circulating Tumor DNA Response In Urothelial Cancer
NCT07183319 ·Status: RECRUITING ·Phase: PHASE2
-
A Biomarker Study to Predict Treatment Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma
NCT07063758 ·Status: ACTIVE_NOT_RECRUITING
-
Study With a Newly Optical Coherence Tomography Probe for Optimizing Bladder Cancer Diagnosis and Treatment
NCT06679920 ·Status: RECRUITING ·Phase: NA
-
Study on the Staging and Prognosis Model of Bladder Cancer
NCT06565923 ·Status: ACTIVE_NOT_RECRUITING
-
In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both?
NCT03174912 ·Status: COMPLETED ·Phase: PHASE4
-
Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab
NCT03263039 ·Status: UNKNOWN ·Phase: PHASE2
-
Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer
NCT02969109 ·Status: COMPLETED
-
Renal Retention in High Grade Upper Tract Urothelial Cancer
NCT05656235 ·Status: RECRUITING ·Phase: PHASE2
-
To Detect the Sensitivity of the UroMark Assay
NCT02781428 ·Status: COMPLETED
-
Confocal Laser Endomicroscopy in the Lower Urinary Tract
NCT03013894 ·Status: COMPLETED
-
Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer Monitor
NCT04100733 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer
NCT06335667 ·Status: RECRUITING ·Phase: NA